Crohn's disease. Inflammatory bowel diseases
Conditions
Interventions
Group 1a:
30 mg CCX507-B or placebo once (in fasted state)
30 mg CCX507-B or placebo once daily (in fasted state)
30 mg CCX507-B or placebo twice daily (in fasted state)
Group 1b:
30 mg CCX507-B or p
Sponsors
ChemoCentryx, Inc.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy male or female 18 - 65 years inclusive BMI 18.0 -30.0 kilograms/meter2 non smoker
Exclusion criteria
Exclusion criteria: Suffering form hepatitis B, hepatitis C, cancer or HIV/AIDS. Participation in another drug study within 60 days prior to randomization. Any donation of blood (products) or significant blood loss within 56 days prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to evaluate the safety and tolerability of single and multiple oral doses of CCX507-B, over a range of 3 dose levels, in healthy male and female subjects. | — |
Secondary
| Measure | Time frame |
|---|---|
| * The effect of food on the PK profile of CCX507-B; and * The relationship between CCX507 plasma concentrations and blockade of the C-C chemokine receptor 9 (CCR9) on circulating leukocytes. | — |
Countries
Netherlands
Outcome results
None listed